Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
71 hedge funds and large institutions have $43.3M invested in Northwest Biotherapeutics, Inc. Common stock in 2014 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 18 reducing their positions, and 17 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 18
11% less funds holding
Funds holding: 80 → 71 (-9)
23% less capital invested
Capital invested by funds: $56.5M → $43.3M (-$13.2M)
46% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $2M
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.76M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.44M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$901K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$872K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$627K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$1.14M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$819K |
| 3 |
D.E. Shaw & Co
New York
|
-$711K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$385K |
| 5 |
SG Americas Securities
New York
|
-$380K |
NWBO Hedge Fund Activity: Q3 2014 in Review
71 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2014, worth a combined $43.3M — down 23% from $56.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of NWBO and 9 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 23 added.
The largest buyer was Northern Trust, adding an estimated $1.76M. The largest seller was Allianz Asset Management, exiting entirely with an estimated $1.14M sold.
- 71 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2014, down from 80 in Q2 2014.
- Funds reported $43.3M of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2014, down 23% quarter-over-quarter.
- 9 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2014 and 17 closed out, a net change of -8 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2014 was Northern Trust, an estimated $1.76M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2014 was Allianz Asset Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q3 2014.